Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

A Phase 1 Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Rn316 In Combination With Atorvastatin In Hypercholesterolemic Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01163851

Enrollment

Registered

2010-07-16

Start date

2010-07-31

Completion date

2011-04-30

Last updated

2018-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Hypercholesterolemia

Keywords

Hypercholesterolemia, Dyslipidemia, LDL, Cholesterol, High Cholesterol, PF-04950615, RN316

Brief summary

The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.

Interventions

BIOLOGICAL4 mg/kg

RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.

BIOLOGICAL0.5 mg/kg

RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* On stable doses of atorvastatin (40 mg daily) for 45 days prior to Day 1. * BMI 18.5 to 40 kg/m2 inclusive, and body weight equal or lower than 150 kg.

Exclusion criteria

* History of a cardiovascular event (e.g., MI ) during the past year. * Poorly controlled Type 1 or Type 2 Diabetes mellitus (definition: uncontrolled diabetes is defined as HBIAc \>9%). * Poorly controlled hypertension (uncontrolled hypertension is defined as a systolic blood pressure greater than 140 mm Hg or a diastolic blood pressure greater than 90 mm Hg, even with treatment). Subjects who have hypertension and are controlled on stable dosages of anti-hypertensive medications can be included.

Design outcomes

Primary

Measure	Time frame	Description
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	—
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	—
Maximum Observed Plasma Concentration (Cmax) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	—
Plasma Decay Half-Life (t1/2) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Plasma decay half-life is the time measured for the plasma concentration of PF-04950615 to decrease by one half.
Systemic Clearance (CL) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	CL is a quantitative measure of the rate at which a drug substance is removed from the body.
Volume of Distribution at Steady State (Vss) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615	0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	—
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4	AUCtau was the AUC from time 0 to the end of the dosing interval, where the dosing interval was 12 hours.
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7	—
Maximum Observed Plasma Concentration (Cmax) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7	—
Plasma Decay Half-Life (t1/2) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7	Plasma decay half-life is the time measured for the plasma concentration of atorvastatin to decrease by one half.
Apparent Oral Clearance (CL/F) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4	Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Apparent Volume of Distribution (Vz/F) of Atorvastatin	0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4	Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Secondary

Measure	Time frame	Description
Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.
Duration of Low Density Lipoprotein (LDL) Lowering Effects	Day 4 to Day 64	In this outcome measure duration of the lipid-lowering effects was reported. Lipid lowering was defined as decrease in LDL-C levels by greater than or equal to 15 percent.
Number of Participants With Toxicity or Intolerable Dose Criteria	Day 1 up to Day 64	Toxicity criteria included any of the following: serious adverse event; increased liver transaminases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]: increased to greater than \[\>\] 5\*upper limit of normal reference range \[ULN\]); increased bilirubin (in absence of ALT or AST elevations, common terminology criteria for adverse events \[CTCAE\] greater than or equal to \[\>=\] Grade 2); pancreatitis, increased serum creatinine (CTCAE \>= Grade 2); creatine kinase, hyperglycemia or hypoglycemia, diarrhea or enteritis or nausea (CTCAE \>= Grade 3); decreased platelet count (less than \[\<\] 100000 per microliter); prolongation of QT interval with Fridericia's Correction (QTcF) (QTcF \>500 millisecond \[msec\] \[CTCAE \>= Grade 3\] or increase from baseline of \>=60 msec) and other considered appropriate by investigator. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Day 1 up to Day 64	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. Adverse events included both serious and non-serious adverse events.
Number of Participants With Treatment-Emergent Adverse Events by Severity	Day 1 up to Day 64	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. AEs were assessed for severity by CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event. Categories with at least 1 participant were reported
Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination	Day 1 up to Day 64	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. Complete physical examination was conducted to assess skin, ears, throat, cardiac, respiratory, gastrointestinal, and musculoskeletal systems for systemic AEs.
Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Day 1 up to Day 64	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. Vital sign parameters body temperature, blood pressure and heart rate were assessed to identify systemic adverse events. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event. Categories with at least 1 participant were reported
Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	Day 1 up to Day 64	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. ECG parameters RR interval, PR interval, QRS complex, QT interval, \[Bazett's Correction\], QTcF interval \[Fridericia's Correction\] were assessed to identify systemic AEs. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event. Categories with at least 1 participant were reported.
Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Day 1 up to Day 64	Laboratory parameters alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, albumin, hemoglobin, protein, amylase, creatine kinase, lipase, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets, white blood cells, bicarbonate, chloride, potassium, sodium, bilirubin, blood urea nitrogen, c-reactive protein , calcium, creatinine, direct bilirubin, glucose, magnesium, phosphate, uric acid, hematocrit, partial thromboplastin time , prothrombin time, red blood cells , urine pH, urine specific gravity were assessed to identify systemic AEs. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade. Categories with at least 1 participant were reported.
Number of Participants With Positive Anti-drug Antibodies (ADA)	Day 1 up to Day 64	Human serum ADA samples of participants who received PF-04950615 (RN316) were analyzed for the presence of anti-PF-04950615 (RN316) antibodies. Results with titer value \>=4.32 nanogram per milliliter of anti-PF-04950615 antibodies were counted as positive. Number of participants with presence of anti-PF-04950615 antibodies were reported in this outcome measure.
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)	Day 1 up to Day 64	An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.
Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.
Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.
Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.
Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64	Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Countries

United States

Participant flow

Participants by arm

Arm	Count
PF-04950615 (RN316) 4 mg/kg + Atorvastatin Participants received single intravenous infusion dose of PF-04950615 (RN316) 4 milligram per kilogram (mg/kg) on Day 4 along with sponsor provided atorvastatin 40 milligram (mg) tablet orally once daily from Day 1 to 7. Participants were on self-administered stable atorvastatin therapy, 40 mg orally once daily prior to Day 1 and after treatment phase (Day 7). Participants were followed up to Day 64.	12
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin Participants received single intravenous infusion dose of PF-04950615 (RN316) 0.5 mg/kg on Day 4 along with sponsor provided atorvastatin 40 mg tablet orally once daily from Day 1 to 7. Participants were on self-administered stable atorvastatin therapy, 40 mg orally once daily prior to Day 1 and after treatment phase (Day 7). Participants were followed up to Day 64.	12
Total	24

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Enrolled but not treated	1	0
Overall Study	Site Closure	0	1

Baseline characteristics

Characteristic	PF-04950615 (RN316) 4 mg/kg + Atorvastatin	PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	3 Participants	3 Participants	6 Participants
Age, Categorical Between 18 and 65 years	9 Participants	9 Participants	18 Participants
Sex: Female, Male Female	7 Participants	5 Participants	12 Participants
Sex: Female, Male Male	5 Participants	7 Participants	12 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	12 / 12	11 / 12
serious Total, serious adverse events	1 / 12	0 / 12

Outcome results

Primary

Apparent Oral Clearance (CL/F) of Atorvastatin

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Apparent Oral Clearance (CL/F) of Atorvastatin	557.50 liter per hour	Standard Deviation 238.33
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Apparent Oral Clearance (CL/F) of Atorvastatin	448.70 liter per hour	Standard Deviation 196.91

Primary

Apparent Volume of Distribution (Vz/F) of Atorvastatin

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' is signifying those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Apparent Volume of Distribution (Vz/F) of Atorvastatin	3950 liter	Standard Deviation 1952.8
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Apparent Volume of Distribution (Vz/F) of Atorvastatin	3353 liter	Standard Deviation 1960.8

Primary

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin

AUCtau was the AUC from time 0 to the end of the dosing interval, where the dosing interval was 12 hours.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin	71.73 nanogram*hour per milliliter	Standard Deviation 32.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin	89.17 nanogram*hour per milliliter	Standard Deviation 33.25

Primary

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615	17960000 nanogram*hour per milliliter	Standard Deviation 2828500
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615	1094000 nanogram*hour per milliliter	Standard Deviation 123640

Primary

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: Pharmacokinetic (PK) parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	17950000 nanogram*hour per milliliter	Standard Deviation 2779600
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615	933800 nanogram*hour per milliliter	Standard Deviation 376350

Primary

Maximum Observed Plasma Concentration (Cmax) of Atorvastatin

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Maximum Observed Plasma Concentration (Cmax) of Atorvastatin	15.79 nanogram per milliliter	Standard Deviation 8.81
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Maximum Observed Plasma Concentration (Cmax) of Atorvastatin	20.68 nanogram per milliliter	Standard Deviation 10.58

Primary

Maximum Observed Plasma Concentration (Cmax) of PF-04950615

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	105000 nanogram per milliliter	Standard Deviation 16587
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Maximum Observed Plasma Concentration (Cmax) of PF-04950615	14030 nanogram per milliliter	Standard Deviation 1680

Primary

Plasma Decay Half-Life (t1/2) of Atorvastatin

Plasma decay half-life is the time measured for the plasma concentration of atorvastatin to decrease by one half.

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Plasma Decay Half-Life (t1/2) of Atorvastatin	5.12 hour	Standard Deviation 1.38
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Plasma Decay Half-Life (t1/2) of Atorvastatin	5.09 hour	Standard Deviation 0.74

Primary

Plasma Decay Half-Life (t1/2) of PF-04950615

Plasma decay half-life is the time measured for the plasma concentration of PF-04950615 to decrease by one half.

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Plasma Decay Half-Life (t1/2) of PF-04950615	157.50 hour	Standard Deviation 33.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Plasma Decay Half-Life (t1/2) of PF-04950615	61.00 hour	Standard Deviation 8.89

Primary

Systemic Clearance (CL) of PF-04950615

CL is a quantitative measure of the rate at which a drug substance is removed from the body.

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Systemic Clearance (CL) of PF-04950615	0.0185 liter per hour	Standard Deviation 0.0041
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Systemic Clearance (CL) of PF-04950615	0.0392 liter per hour	Standard Deviation 0.0031

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin

Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 and 12 hrs post-dose on Day 4, pre atorvastatin dose on Day 5, 6 and 7

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (MEDIAN)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin	1.16 hour
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin	1.00 hour

Primary

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest.

Arm	Measure	Value (MEDIAN)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	2.59 hour
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615	4.00 hour

Primary

Volume of Distribution at Steady State (Vss) of PF-04950615

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

Time frame: 0 (pre-dose on Day 4), 1, 4, 8 and 12 hours (hrs) post intravenous PF-04950615 (RN316) dose, pre atorvastatin dose on Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Population: PK parameter analysis population included all enrolled participants who were treated and had at least 1 of the PK parameters of interest. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure for each group respectively.

Arm	Measure	Value (GEOMETRIC_MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Volume of Distribution at Steady State (Vss) of PF-04950615	4.248 liter	Standard Deviation 1.099
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Volume of Distribution at Steady State (Vss) of PF-04950615	3.436 liter	Standard Deviation 0.583

Secondary

Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Population: Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest. Here, 'Number Participants Analyzed' is signifying those participants who were evaluable for particular category for each arm group respectively.

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	6.80 milligram per deciliter	Standard Deviation 8.3
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	10.30 milligram per deciliter	Standard Deviation 10.87
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	3.40 milligram per deciliter	Standard Deviation 10.93
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	7.80 milligram per deciliter	Standard Deviation 10.73
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	5.70 milligram per deciliter	Standard Deviation 11.13
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	6.50 milligram per deciliter	Standard Deviation 8.64
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-1.70 milligram per deciliter	Standard Deviation 10.79
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	4.40 milligram per deciliter	Standard Deviation 11.77
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	7.50 milligram per deciliter	Standard Deviation 13.43
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	0.50 milligram per deciliter	Standard Deviation 10.82
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-3.00 milligram per deciliter	Standard Deviation 10.95
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	22.10 milligram per deciliter	Standard Deviation 19.44
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	2.80 milligram per deciliter	Standard Deviation 8.7
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-5.60 milligram per deciliter	Standard Deviation 8.07
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-1.50 milligram per deciliter	Standard Deviation 9.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	12.10 milligram per deciliter	Standard Deviation 18.48
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	16.10 milligram per deciliter	Standard Deviation 18.71
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	11.40 milligram per deciliter	Standard Deviation 27.34
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	11.50 milligram per deciliter	Standard Deviation 15.09
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	14.90 milligram per deciliter	Standard Deviation 15.96
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	5.20 milligram per deciliter	Standard Deviation 22.03
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	24.50 milligram per deciliter	Standard Deviation 12.51

Secondary

Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-41.90 milligram per deciliter	Standard Deviation 19.41
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-41.10 milligram per deciliter	Standard Deviation 15.09
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-28.30 milligram per deciliter	Standard Deviation 12.57
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-27.30 milligram per deciliter	Standard Deviation 7.48
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-44.00 milligram per deciliter	Standard Deviation 17.67
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-10.40 milligram per deciliter	Standard Deviation 10.53
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-22.10 milligram per deciliter	Standard Deviation 10.05
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	-5.10 milligram per deciliter	Standard Deviation 15.7
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-45.80 milligram per deciliter	Standard Deviation 17.61
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	2.30 milligram per deciliter	Standard Deviation 10.7
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-10.90 milligram per deciliter	Standard Deviation 7.48
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	5.80 milligram per deciliter	Standard Deviation 20.99
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-13.10 milligram per deciliter	Standard Deviation 8.49
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-24.90 milligram per deciliter	Standard Deviation 12.88
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-29.50 milligram per deciliter	Standard Deviation 16.75
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-21.70 milligram per deciliter	Standard Deviation 19.84
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-3.30 milligram per deciliter	Standard Deviation 18.78
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-1.10 milligram per deciliter	Standard Deviation 23.99
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-2.70 milligram per deciliter	Standard Deviation 19.76
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-0.60 milligram per deciliter	Standard Deviation 18.47
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-4.60 milligram per deciliter	Standard Deviation 20.74
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	4.70 milligram per deciliter	Standard Deviation 15.51

Secondary

Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	4.50 milligram per deciliter	Standard Deviation 8.01
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	3.80 milligram per deciliter	Standard Deviation 5.52
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-0.90 milligram per deciliter	Standard Deviation 4.41
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	6.10 milligram per deciliter	Standard Deviation 6.59
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	6.70 milligram per deciliter	Standard Deviation 4.65
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	2.80 milligram per deciliter	Standard Deviation 6.27
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-2.10 milligram per deciliter	Standard Deviation 4.16
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	2.70 milligram per deciliter	Standard Deviation 5.26
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	6.50 milligram per deciliter	Standard Deviation 6.53
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	-0.0 milligram per deciliter	Standard Deviation 6.02
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-1.30 milligram per deciliter	Standard Deviation 5.6
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	2.40 milligram per deciliter	Standard Deviation 7.95
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-2.20 milligram per deciliter	Standard Deviation 7.95
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-2.40 milligram per deciliter	Standard Deviation 11.71
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-2.40 milligram per deciliter	Standard Deviation 12.63
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	5.90 milligram per deciliter	Standard Deviation 5.13
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	2.80 milligram per deciliter	Standard Deviation 5.41
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	0.50 milligram per deciliter	Standard Deviation 5.99
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	1.90 milligram per deciliter	Standard Deviation 8.2
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	3.10 milligram per deciliter	Standard Deviation 5.39
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	1.70 milligram per deciliter	Standard Deviation 7.71
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	4.20 milligram per deciliter	Standard Deviation 9.22

Secondary

Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-52.40 milligram per deciliter	Standard Deviation 35.31
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-55.50 milligram per deciliter	Standard Deviation 23.64
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-33.30 milligram per deciliter	Standard Deviation 22.42
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-32.30 milligram per deciliter	Standard Deviation 15.64
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-57.20 milligram per deciliter	Standard Deviation 30.71
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-11.40 milligram per deciliter	Standard Deviation 13.27
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-28.50 milligram per deciliter	Standard Deviation 17.22
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	-1.50 milligram per deciliter	Standard Deviation 22.25
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-56.90 milligram per deciliter	Standard Deviation 35.21
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	6.20 milligram per deciliter	Standard Deviation 24.62
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-14.30 milligram per deciliter	Standard Deviation 17.79
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	12.10 milligram per deciliter	Standard Deviation 33.42
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-16.2 milligram per deciliter	Standard Deviation 11.56
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-34.00 milligram per deciliter	Standard Deviation 19.13
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-47.20 milligram per deciliter	Standard Deviation 20.66
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-25.90 milligram per deciliter	Standard Deviation 31.94
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	2.10 milligram per deciliter	Standard Deviation 36.01
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	9.40 milligram per deciliter	Standard Deviation 33.12
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	3.40 milligram per deciliter	Standard Deviation 33.09
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	8.80 milligram per deciliter	Standard Deviation 34.18
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	4.10 milligram per deciliter	Standard Deviation 29.02
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	10.90 milligram per deciliter	Standard Deviation 35.79

Secondary

Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-62.50 milligram per deciliter	Standard Deviation 39.4
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-60.00 milligram per deciliter	Standard Deviation 29.56
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-36.40 milligram per deciliter	Standard Deviation 24.5
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-35.00 milligram per deciliter	Standard Deviation 18.14
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-68.80 milligram per deciliter	Standard Deviation 32.78
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-9.00 milligram per deciliter	Standard Deviation 17.87
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-31.20 milligram per deciliter	Standard Deviation 20.31
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	6.50 milligram per deciliter	Standard Deviation 32.76
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-69.00 milligram per deciliter	Standard Deviation 35.01
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	12.10 milligram per deciliter	Standard Deviation 20.13
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	12.60 milligram per deciliter	Standard Deviation 21.9
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	12.70 milligram per deciliter	Standard Deviation 35.12
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-19.40 milligram per deciliter	Standard Deviation 15.16
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-35.90 milligram per deciliter	Standard Deviation 22.27
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-47.60 milligram per deciliter	Standard Deviation 24.04
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-30.10 milligram per deciliter	Standard Deviation 36.18
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	4.70 milligram per deciliter	Standard Deviation 40.14
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	7.90 milligram per deciliter	Standard Deviation 39.76
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	3.50 milligram per deciliter	Standard Deviation 41.05
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	6.60 milligram per deciliter	Standard Deviation 38.85
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	3.10 milligram per deciliter	Standard Deviation 37.89
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	14.30 milligram per deciliter	Standard Deviation 39.36

Secondary

Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-58.00 milligram per deciliter	Standard Deviation 39.02
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-56.30 milligram per deciliter	Standard Deviation 28.61
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-37.30 milligram per deciliter	Standard Deviation 25.72
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-28.90 milligram per deciliter	Standard Deviation 19.61
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-61.30 milligram per deciliter	Standard Deviation 34.91
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-6.30 milligram per deciliter	Standard Deviation 18.51
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-33.30 milligram per deciliter	Standard Deviation 19.04
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	9.30 milligram per deciliter	Standard Deviation 31.92
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-62.60 milligram per deciliter	Standard Deviation 32.81
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	12.10 milligram per deciliter	Standard Deviation 23
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-13.90 milligram per deciliter	Standard Deviation 19.48
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	15.10 milligram per deciliter	Standard Deviation 31.48
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-21.60 milligram per deciliter	Standard Deviation 15.04
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-38.30 milligram per deciliter	Standard Deviation 18.03
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-50.00 milligram per deciliter	Standard Deviation 20.5
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-24.30 milligram per deciliter	Standard Deviation 38.29
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	7.50 milligram per deciliter	Standard Deviation 38.05
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	8.40 milligram per deciliter	Standard Deviation 36.28
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	5.30 milligram per deciliter	Standard Deviation 36.43
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	9.80 milligram per deciliter	Standard Deviation 38.4
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	4.80 milligram per deciliter	Standard Deviation 34.39
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	18.50 milligram per deciliter	Standard Deviation 34.69

Secondary

Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-19.60 milligram per deciliter	Standard Deviation 41.4
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-22.20 milligram per deciliter	Standard Deviation 54.24
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	8.10 milligram per deciliter	Standard Deviation 38.09
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-13.10 milligram per deciliter	Standard Deviation 42.48
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	-4.30 milligram per deciliter	Standard Deviation 45.63
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	11.60 milligram per deciliter	Standard Deviation 57.86
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	11.70 milligram per deciliter	Standard Deviation 24.23
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	26.20 milligram per deciliter	Standard Deviation 63.42
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-17.40 milligram per deciliter	Standard Deviation 21.51
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	29.60 milligram per deciliter	Standard Deviation 53.23
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	9.20 milligram per deciliter	Standard Deviation 61.82
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 64	3.10 milligram per deciliter	Standard Deviation 31.78
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 5	-15.80 milligram per deciliter	Standard Deviation 38.46
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 6	-9.90 milligram per deciliter	Standard Deviation 31.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 7	-6.90 milligram per deciliter	Standard Deviation 44.25
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 15	-21.10 milligram per deciliter	Standard Deviation 56.39
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 22	13.60 milligram per deciliter	Standard Deviation 52.71
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 29	-8.20 milligram per deciliter	Standard Deviation 60.64
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 36	-0.30 milligram per deciliter	Standard Deviation 70.24
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 43	-10.90 milligram per deciliter	Standard Deviation 64.52
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 50	-4.90 milligram per deciliter	Standard Deviation 79.62
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Change at Day 57	16.50 milligram per deciliter	Standard Deviation 56.65

Secondary

Duration of Low Density Lipoprotein (LDL) Lowering Effects

In this outcome measure duration of the lipid-lowering effects was reported. Lipid lowering was defined as decrease in LDL-C levels by greater than or equal to 15 percent.

Time frame: Day 4 to Day 64

Population: Pharmacodynamic analysis population included all enrolled participants who received any amount of study medication and had at least 1 pharmacodynamic parameter of interest.

Arm	Measure	Value (MEDIAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Duration of Low Density Lipoprotein (LDL) Lowering Effects	48.5 days	Full Range 16.36
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Duration of Low Density Lipoprotein (LDL) Lowering Effects	18.0 days	Full Range 15.68

Secondary

Number of Participants With Positive Anti-drug Antibodies (ADA)

Human serum ADA samples of participants who received PF-04950615 (RN316) were analyzed for the presence of anti-PF-04950615 (RN316) antibodies. Results with titer value \>=4.32 nanogram per milliliter of anti-PF-04950615 antibodies were counted as positive. Number of participants with presence of anti-PF-04950615 antibodies were reported in this outcome measure.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Positive Anti-drug Antibodies (ADA)	4 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Positive Anti-drug Antibodies (ADA)	0 Participants

Secondary

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. ECG parameters RR interval, PR interval, QRS complex, QT interval, \[Bazett's Correction\], QTcF interval \[Fridericia's Correction\] were assessed to identify systemic AEs. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event. Categories with at least 1 participant were reported.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	AEs (All causalities)	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	Treatment related AEs	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	Grade 1 AEs: (All causalities)	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	AEs (All causalities)	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	Treatment related AEs	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters	Grade 1 AEs: (All causalities)	1 Participants

Secondary

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters

Laboratory parameters alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, albumin, hemoglobin, protein, amylase, creatine kinase, lipase, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets, white blood cells, bicarbonate, chloride, potassium, sodium, bilirubin, blood urea nitrogen, c-reactive protein , calcium, creatinine, direct bilirubin, glucose, magnesium, phosphate, uric acid, hematocrit, partial thromboplastin time , prothrombin time, red blood cells , urine pH, urine specific gravity were assessed to identify systemic AEs. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. Same participant may be reported in more than 1 CTCAE severity grade. Categories with at least 1 participant were reported.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	AEs (All causalities)	2 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Treatment related AEs	2 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 1 AEs: (All causalities)	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 1 AEs: (Treatment related)	2 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 2 AEs: (Treatment related)	1 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 3 AEs: (Treatment related)	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 2 AEs: (Treatment related)	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	AEs (All causalities)	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 1 AEs: (Treatment related)	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Treatment related AEs	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 3 AEs: (Treatment related)	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters	Grade 1 AEs: (All causalities)	1 Participants

Secondary

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination	0 Participants

Secondary

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. Vital sign parameters body temperature, blood pressure and heart rate were assessed to identify systemic adverse events. AEs (all causalities), treatment related AEs and CTCAE severity grades for AEs were reported. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event. Categories with at least 1 participant were reported

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	AEs (All causalities)	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Treatment related AEs	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Grade 1 AEs: (All causalities)	0 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Grade 2 AEs: (All causalities)	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Grade 2 AEs: (All causalities)	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	AEs (All causalities)	2 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Grade 1 AEs: (All causalities)	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs	Treatment related AEs	0 Participants

Secondary

Number of Participants With Toxicity or Intolerable Dose Criteria

Toxicity criteria included any of the following: serious adverse event; increased liver transaminases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]: increased to greater than \[\>\] 5\*upper limit of normal reference range \[ULN\]); increased bilirubin (in absence of ALT or AST elevations, common terminology criteria for adverse events \[CTCAE\] greater than or equal to \[\>=\] Grade 2); pancreatitis, increased serum creatinine (CTCAE \>= Grade 2); creatine kinase, hyperglycemia or hypoglycemia, diarrhea or enteritis or nausea (CTCAE \>= Grade 3); decreased platelet count (less than \[\<\] 100000 per microliter); prolongation of QT interval with Fridericia's Correction (QTcF) (QTcF \>500 millisecond \[msec\] \[CTCAE \>= Grade 3\] or increase from baseline of \>=60 msec) and other considered appropriate by investigator. CTCAE Grade 4.0: Grade 1= mild; Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening consequences and Grade 5= death related to adverse event.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Toxicity or Intolerable Dose Criteria	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Toxicity or Intolerable Dose Criteria	0 Participants

Secondary

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 64 days that were absent before treatment or that worsened relative to pretreatment state. Adverse events included both serious and non-serious adverse events.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	12 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	11 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants

Secondary

Number of Participants With Treatment-Emergent Adverse Events by Severity

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 1 AEs	5 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 2 AEs	4 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 3 AEs	2 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Unknown	1 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Unknown	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 1 AEs	8 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 3 AEs	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Emergent Adverse Events by Severity	Grade 2 AEs	3 Participants

Secondary

Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame: Day 1 up to Day 64

Population: Safety analysis population included all participants who met the study enrollment criteria and had received any amount of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	6 Participants
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)	SAEs	0 Participants
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)	AEs	0 Participants

Secondary

Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	5.10 percent change	Standard Deviation 6.31
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	7.30 percent change	Standard Deviation 7.64
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	2.90 percent change	Standard Deviation 7.14
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	5.80 percent change	Standard Deviation 7.73
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	4.40 percent change	Standard Deviation 8.27
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	4.50 percent change	Standard Deviation 5.77
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-1.00 percent change	Standard Deviation 7.27
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	3.40 percent change	Standard Deviation 8.71
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	5.20 percent change	Standard Deviation 9.94
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	0.80 percent change	Standard Deviation 7.48
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-1.90 percent change	Standard Deviation 7.48
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	16.90 percent change	Standard Deviation 14.18
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	2.10 percent change	Standard Deviation 6.61
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-4.20 percent change	Standard Deviation 6.8
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-0.80 percent change	Standard Deviation 7.97
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	9.10 percent change	Standard Deviation 12.52
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	11.50 percent change	Standard Deviation 11.39
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	7.80 percent change	Standard Deviation 17.55
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	8.80 percent change	Standard Deviation 11.09
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	11.60 percent change	Standard Deviation 12.44
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	3.50 percent change	Standard Deviation 16.45
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	18.80 percent change	Standard Deviation 7.84

Secondary

Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-48.60 percent change	Standard Deviation 13.82
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	-48.80 percent change	Standard Deviation 9.97
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-33.80 percent change	Standard Deviation 12.27
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	-33.80 percent change	Standard Deviation 8.98
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-51.50 percent change	Standard Deviation 11.04
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	-13.70 percent change	Standard Deviation 13.7
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-26.90 percent change	Standard Deviation 11.01
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	-5.80 percent change	Standard Deviation 18.03
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	-53.70 percent change	Standard Deviation 10.37
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	3.00 percent change	Standard Deviation 12.82
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-13.50 percent change	Standard Deviation 9.25
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	11.50 percent change	Standard Deviation 25.5
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-17.10 percent change	Standard Deviation 11.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-31.10 percent change	Standard Deviation 13.84
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-36.10 percent change	Standard Deviation 15.68
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-24.80 percent change	Standard Deviation 18.18
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-0.70 percent change	Standard Deviation 19.21
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	3.80 percent change	Standard Deviation 26.31
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	1.50 percent change	Standard Deviation 22.64
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	2.70 percent change	Standard Deviation 18.81
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	-1.50 percent change	Standard Deviation 21.38
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	9.40 percent change	Standard Deviation 19.89

Secondary

Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	11.10 percent change	Standard Deviation 19.48
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	7.80 percent change	Standard Deviation 11.5
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-1.10 percent change	Standard Deviation 9.29
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	14.50 percent change	Standard Deviation 15.67
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	13.90 percent change	Standard Deviation 9.65
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	6.10 percent change	Standard Deviation 13.89
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-3.60 percent change	Standard Deviation 8.24
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	6.10 percent change	Standard Deviation 11.93
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	14.00 percent change	Standard Deviation 15.04
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	0.50 percent change	Standard Deviation 12.37
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-2.50 percent change	Standard Deviation 11.27
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	8.20 percent change	Standard Deviation 12.15
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-1.70 percent change	Standard Deviation 10.93
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-0.90 percent change	Standard Deviation 18.31
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-0.90 percent change	Standard Deviation 18.01
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	13.40 percent change	Standard Deviation 12.4
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	8.00 percent change	Standard Deviation 11.23
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	3.00 percent change	Standard Deviation 11.72
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	7.50 percent change	Standard Deviation 17.15
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	8.70 percent change	Standard Deviation 8.79
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	6.70 percent change	Standard Deviation 14.2
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	14.00 percent change	Standard Deviation 19.37

Secondary

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-61.10 percent change	Standard Deviation 31.98
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	-68.20 percent change	Standard Deviation 15.59
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-38.90 percent change	Standard Deviation 24.15
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	-41.80 percent change	Standard Deviation 18.87
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-71.60 percent change	Standard Deviation 21.89
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	-14.70 percent change	Standard Deviation 17.1
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-33.80 percent change	Standard Deviation 20.61
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	1.40 percent change	Standard Deviation 24.8
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	-68.70 percent change	Standard Deviation 22.2
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	13.40 percent change	Standard Deviation 31.22
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-15.70 percent change	Standard Deviation 23.36
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	25.60 percent change	Standard Deviation 42.94
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-27.30 percent change	Standard Deviation 23.6
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-47.00 percent change	Standard Deviation 30.57
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-65.10 percent change	Standard Deviation 31.82
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-33.30 percent change	Standard Deviation 29.8
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	11.40 percent change	Standard Deviation 46.23
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	21.60 percent change	Standard Deviation 46.26
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	14.90 percent change	Standard Deviation 36.9
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	19.70 percent change	Standard Deviation 38.86
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	13.70 percent change	Standard Deviation 37.36
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	23.60 percent change	Standard Deviation 47.93

Secondary

Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-56.00 percent change	Standard Deviation 26.05
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	-57.30 percent change	Standard Deviation 16.6
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-32.80 percent change	Standard Deviation 18.81
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	-35.70 percent change	Standard Deviation 16.64
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-63.90 percent change	Standard Deviation 18
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	-9.40 percent change	Standard Deviation 16.55
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-28.70 percent change	Standard Deviation 16.69
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	7.80 percent change	Standard Deviation 26.93
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	-63.90 percent change	Standard Deviation 17.86
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	15.60 percent change	Standard Deviation 20.3
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-9.90 percent change	Standard Deviation 20.47
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	21.20 percent change	Standard Deviation 35.27
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-20.30 percent change	Standard Deviation 15.38
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-37.60 percent change	Standard Deviation 26.74
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-50.00 percent change	Standard Deviation 26.78
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-25.40 percent change	Standard Deviation 26.16
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	14.70 percent change	Standard Deviation 40.72
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	16.10 percent change	Standard Deviation 40.69
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	14.00 percent change	Standard Deviation 36.59
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	14.30 percent change	Standard Deviation 35.8
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	12.90 percent change	Standard Deviation 38.29
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	23.80 percent change	Standard Deviation 44.36

Secondary

Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 (RN316) administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-6.10 percent change	Standard Deviation 41.62
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	-15.90 percent change	Standard Deviation 32.23
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	5.00 percent change	Standard Deviation 21.2
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	-7.90 percent change	Standard Deviation 25.94
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-2.20 percent change	Standard Deviation 30.73
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	12.60 percent change	Standard Deviation 42.61
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	7.40 percent change	Standard Deviation 20.29
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	20.10 percent change	Standard Deviation 45.52
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	-14.60 percent change	Standard Deviation 20.02
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	28.60 percent change	Standard Deviation 42.51
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	11.20 percent change	Standard Deviation 65.46
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	7.60 percent change	Standard Deviation 30.24
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-3.30 percent change	Standard Deviation 24.88
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	1.10 percent change	Standard Deviation 22.05
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	0.50 percent change	Standard Deviation 27.67
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-1.40 percent change	Standard Deviation 35.76
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	19.90 percent change	Standard Deviation 42.17
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	0.80 percent change	Standard Deviation 34.11
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	12.20 percent change	Standard Deviation 45.69
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	3.20 percent change	Standard Deviation 33.05
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	12.10 percent change	Standard Deviation 49.12
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	22.20 percent change	Standard Deviation 41.65

Secondary

Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Baseline value calculated as average of Day 2 and Day 4 measurements prior to PF-04950615 administration.

Time frame: Baseline, Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57, 64

Arm	Measure	Group	Value (MEAN)	Dispersion
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	-39.40 percent change	Standard Deviation 14.5
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-21.20 percent change	Standard Deviation 10.16
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	-36.30 percent change	Standard Deviation 14
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-35.40 percent change	Standard Deviation 19.65
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	-18.90 percent change	Standard Deviation 10.34
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-8.30 percent change	Standard Deviation 11.81
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	-3.70 percent change	Standard Deviation 11.17
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	-38.40 percent change	Standard Deviation 16.7
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	7.50 percent change	Standard Deviation 19.31
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	10.10 percent change	Standard Deviation 14.86
PF-04950615 (RN316) 4 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-23.10 percent change	Standard Deviation 14.16
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 64	12.50 percent change	Standard Deviation 18.07
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 5	-14.60 percent change	Standard Deviation 8.87
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 6	-26.20 percent change	Standard Deviation 10.56
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 7	-34.10 percent change	Standard Deviation 11.39
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 15	-14.40 percent change	Standard Deviation 18.89
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 22	7.40 percent change	Standard Deviation 21.95
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 29	7.40 percent change	Standard Deviation 19.86
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 36	7.00 percent change	Standard Deviation 21.5
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 43	9.00 percent change	Standard Deviation 21.22
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 50	6.00 percent change	Standard Deviation 19.62
PF-04950615 (RN316) 0.5 mg/kg + Atorvastatin	Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64	Percent change at Day 57	14.30 percent change	Standard Deviation 20.05

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Apparent Oral Clearance (CL/F) of Atorvastatin

Apparent Volume of Distribution (Vz/F) of Atorvastatin

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Atorvastatin

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC0-inf) of PF-04950615

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615

Maximum Observed Plasma Concentration (Cmax) of Atorvastatin

Maximum Observed Plasma Concentration (Cmax) of PF-04950615

Plasma Decay Half-Life (t1/2) of Atorvastatin

Plasma Decay Half-Life (t1/2) of PF-04950615

Systemic Clearance (CL) of PF-04950615

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Atorvastatin

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615

Volume of Distribution at Steady State (Vss) of PF-04950615

Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting Apolipoprotein B (ApoB) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting Non High-density Lipoprotein-Cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Change From Baseline in Fasting Triglycerides at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Duration of Low Density Lipoprotein (LDL) Lowering Effects

Number of Participants With Positive Anti-drug Antibodies (ADA)

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Electrocardiogram (ECG) Parameters

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Laboratory Parameters

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Physical Examination

Number of Participants With Systemic Treatment Emergent Adverse Events Identified by Vital Signs

Number of Participants With Toxicity or Intolerable Dose Criteria

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of Participants With Treatment-Emergent Adverse Events by Severity

Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)

Percent Change From Baseline in Fasting Apolipoprotein A1 (ApoA1) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Fasting High-Density Lipoprotein (HDL) Cholesterol Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Fasting Non-High-density Lipoprotein-cholesterol (Non-HDL-C) at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Fasting Triglycerides Values at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64

Percent Change From Baseline in Total Cholesterol at Day 5, 6, 7, 15, 22, 29, 36, 43, 50, 57 and 64